Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03613363 · ClinicalTrials.gov registry record · NA
Engineering Evaluation of the Helix Ventilator
A NA study of Pediatric ALL and Pulmonary Disease, sponsored by Philips Respironics.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03613363: Completed NA study of Pediatric ALL and Pulmonary Disease, sponsored by Philips Respironics.
NCT03613363 is a NA study of Pediatric ALL and Pulmonary Disease that has completed, run by Philips Respironics. The registered enrollment target is 20 participants, below the 1,647-participant average among 21 other Pediatric ALL trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03613363, a NA study of Pediatric ALL and Pulmonary Disease, has completed, sponsored by Philips Respironics.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be used to evaluate and observe the overall performance and controls of the Helix ventilator. Pressure and flow data between participants' current devices and the Helix ventilator will be assessed in either invasive or non-invasive ventilation. To evaluate ventilator performance, pressure and waveform data will be assessed as well. Also, patient and caregiver feedback will be captured. The target population is infants to adults weighing more than 5kg. Participants will be recruited by Boston Children's Health Physician's Group. Up to thirty participants will be enrolled in the study.
Primary Outcome
Proximal pressure from the participant's Trilogy Evo ventilator and current device
Conditions Studied
Interventions
- DEVICE Helix Ventilator
Study Locations (1)
New York
- New York Medical College - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2021-09-07 |
| Phase | NA |
What the finished NCT03613363 record still lists
NCT03613363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,647-participant average among 21 other Pediatric ALL trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Pediatric ALL appearing as the primary indexed condition, and to 1 intervention - of which Helix Ventilator is the first listed.
NCT03613363 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03613363 about?
NCT03613363 is a clinical study titled "Engineering Evaluation of the Helix Ventilator". This study will be used to evaluate and observe the overall performance and controls of the Helix ventilator. Pressure and flow data between participants' current devices and the Helix ventilator will be assessed in either invasive or non-invasive ventilation. To evaluate ventilator performance, pre...
What is the current status of trial NCT03613363?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-06-06. Estimated completion is 2021-09-07.
What conditions does trial NCT03613363 study?
This clinical trial studies the following conditions: Pediatric ALL, Pulmonary Disease, Respiratory Disease.
What interventions are being tested in trial NCT03613363?
The interventions under investigation include: Helix Ventilator (DEVICE).
Who is sponsoring clinical trial NCT03613363?
This trial is sponsored by Philips Respironics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03613363 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric ALL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03613363's enrollment target sits among peer trials
20 20th of 21 higher than 1 of 21 other Pediatric ALL trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric ALL trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
RECRUITING · NA
-
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
RECRUITING · NA
-
Feasibility/Acceptability of Attentional-Control Training in Survivors
RECRUITING · NA
-
HEalth Advocate for Liver Transplant - Pilot
RECRUITING · NA
-
Multicenter HomeVENT: Home Values and Experiences Navigation Track
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI